

Munich (DE) / Schlieren, Zurich (CH), 7 June 2022, 07:30 am CET

Gimv co-leads CHF 71M (USD 74M) Series B financing in ImmunOs Therapeutics to develop novel therapies in oncology and autoimmune disease.

ImmunOs Therapeutics AG (“ImmunOs”), a biotech company focused on a new class of HLA-based therapies for the treatment of cancer and autoimmune diseases today announced the closing of a CHF 71M (USD 74M) Series B financing. The round was co-led by Gimv, Samsara Biocapital and Lightspeed Venture Partners, with significant participation from Mission Biocapital, GL Capital, Peak6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq.

ImmunOs Therapeutics AG (www.immunotherapeutics.com) leverages its proprietary platform and knowledge based on master regulators of immunity (i.e. HLA, *human leukocyte antigens*) to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The Company has identified specific HLA molecules known to activate the immune system and utilizes them as the backbone of novel therapies capable of stimulating both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells.

ImmunOs’ lead program is a multi-functional fusion protein that blocks specific immune-regulatory receptors (LILRB, *leukocyte immunoglobulin-like* and KIR, *killer cell immunoglobulin-like*) to initiate and sustain anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

The proceeds of the Series B will be used to fund the clinical development of ImmunOs’ lead program, IOS-1002, through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs. IOS-1002 will enter a Phase 1 clinical trial in the second half of 2022.

Additionally, ImmunOs has established a U.S. subsidiary to further expand its international reach, execute future U.S. clinical trials, and strengthen its transatlantic operations and team.

Andreas Jurgeit, Partner at Gimv: *“ImmunOs’ approach of identifying HLA molecules with naturally optimized affinity and specificity profiles is not just elegant but also truly differentiated – a novel modality leveraging the co-evolution of immune-regulatory mechanisms. We are extremely excited by the progress being made at ImmunOs and proud to support the team towards clinical validation for the benefit of patients.”*

Christoph Kocher, Associate at Gimv, added: *“ImmunOs’ vision of leveraging natural HLA biology to address major unmet needs in patients fully embodies the mission of Gimv’s Life Sciences platform: Building leading companies that have a lasting impact on patients and society.”*

For further information, we refer to the companies press release in the attachment.

ABOUT GIMV

Gimv is a European investment company, listed on Euronext Brussels. With 40 years' experience in private equity, Gimv currently has EUR 2 billion of assets under management. The portfolio contains around 60 portfolio companies, with combined turnover of EUR 3.1 billion and more than 18,000 employees.

As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv's five investment platforms are Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Each platform works with an experienced team across Gimv's home markets of Benelux, France and DACH, supported by an extended international network of experts.

Further information on Gimv can be found on www.gimv.com.

For further information please contact:

Andreas Jurgeit, Partner in Gimv's Life Science team

T +49 89 4423 27 500 – andreas.jurgeit@gimv.com

Christoph Kocher, Associate in Gimv's Life Sciences team

T +49 89 4423 27 519 – christoph.kocher@gimv.com

Kristof Vande Capelle, Chief Financial Officer

T +32 3 290 22 17 – kristof.vandecapelle@gimv.com



ImmunOs Therapeutics Raises \$74 Million Series B Financing Round

- *New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint*
- *Company establishes U.S. subsidiary to accelerate international operations*

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – June 7, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling \$74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. In connection with the financing, Shelley Chu, MD, PhD, Partner at Lightspeed, Marcos Milla, PhD, Venture Partner at Samsara, and Andreas Jurgeit, PhD, Partner at Gimv, will join the Company's Board of Directors, which currently includes Reinhard Ambros, PhD, Chairperson and former Head of the Novartis Venture Fund, Daniel Vasella, MD, Vice Chairperson and former Chairperson and CEO of Novartis AG, Markus Hosang, PhD, General Partner at BioMed Partners, Michael Baran, PhD, Partner at Pfizer Ventures, and Sean R. Smith, CEO of ImmunOs.

The proceeds of the Series B will be used to fund the clinical development of ImmunOs' lead program, IOS-1002 (formerly iosH2), through Phase 2 clinical trials and to progress additional oncology and autoimmune disease programs within the Company's HLA-based pipeline towards clinical development. IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that targets key components of the innate immune system, including LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1, and synergizes with the adaptive immune system, thereby leading to profound anti-tumor activity. A Phase 1 clinical trial is planned to start in the second half of 2022.

Additionally, ImmunOs has established a U.S. subsidiary to further expand its international reach, execute future U.S. clinical trials, and strengthen its transatlantic operations and team.

"We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors," said Sean R. Smith, CEO of ImmunOs Therapeutics. "The raise underlines our promising, first-in-class immunotherapy approach for the treatment of both solid and liquid tumors. The funding allows us to advance our lead program, IOS-1002, into clinical trials, expand our pipeline in oncology and autoimmune disease, and strengthen our transatlantic operations. We are honored that renowned investors such as Samsara, Lightspeed, Gimv, Mission BioCapital, GL Capital, PEAK6, and Fiscus have joined our investor base."

“We are excited to invest in ImmunOs Therapeutics with its innovative HLA-based technology platform, expert leadership team, and strong syndicate of investors,” said Shelley Chu, MD, PhD, Partner at Lightspeed Venture Partners. “The Company is ideally positioned to advance its potentially first-in-class immunotherapies for the benefit of patients with limited therapeutic options. We look forward to supporting ImmunOs’ success.”

“Myeloid checkpoint therapeutics are potentially the next major breakthrough in immuno-oncology, and we believe ImmunOs Therapeutics will contribute exciting medicines in this rapidly evolving field to help patients suffering from cancer,” continued Marcos Milla, PhD, Venture Partner at Samsara. “We look forward to generating data from the initial clinical trials of IOS-1002.”

“ImmunOs’ approach of identifying HLA molecules with naturally optimized affinity and specificity profiles is not just elegant but also truly differentiated – a novel modality leveraging the co-evolution of immune-regulatory mechanisms,” stated Andreas Jurgeit, PhD, Partner at Gimv. “We are extremely excited by the progress being made at ImmunOs and proud to support the team towards clinical validation for the benefit of patients.”

###

About ImmunOs Therapeutics AG

ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The Company has identified specific HLA molecules known to activate the immune system and is utilizing these HLA molecules as the backbone of novel therapies capable of stimulating both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs’ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

For more information, please visit www.immunotherapeutics.com

Company Contact

ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren (Zurich Area), Switzerland
info@immunotherapeutics.com

Media Inquiries

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /Tel. +49 30 23 63 27 68